Premium
Antiepileptic drugs in the preventive treatment of migraine in children and adolescents
Author(s) -
Vollono Catello,
Ferraro Diana,
Valeriani Massimiliano
Publication year - 2007
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.20201
Subject(s) - topiramate , tolerability , zonisamide , medicine , migraine , levetiracetam , gabapentin , valproic acid , epilepsy , pediatrics , randomized controlled trial , anticonvulsant , adverse effect , anesthesia , pharmacology , psychiatry , alternative medicine , pathology
Migraine prevalence in childhood ranges from 2.7 to 10% causing a significant impact on quality of life. No drugs are currently approved for use in the prevention of pediatric migraine. Antiepileptic drugs such as valproate and topiramate have been approved for the preventive treatment of migraine in adults. The present study aimed at reviewing evidence on the efficacy and safety of antiepileptic drugs in the preventive treatment of migraine in children and adolescents. We searched PubMed from 1988 to May 2007 and reviewed, abstracted, and classified relevant literature. Thirteen studies were reviewed. Data from randomized controlled trials are available only for valproate and topiramate. They show that both topiramate and valproate are effective in reducing headache frequency, intensity, and duration. As for safety and tolerability, topiramate is well tolerated, while there are insufficient data regarding the tolerability of valproate. Open‐label or retrospective studies suggest that levetiracetam, zonisamide, and gabapentin are effective, but further evidence is warranted to confirm these data. Drug Dev Res 68:355–359, 2007. © 2007 Wiley‐Liss, Inc.